Clinic
ST Joseph Hospital of Nashua NH
ST Joseph Hospital of Nashua NH was paid $13.00M by Medicaid between Jan 2018 and Dec 2024, across 224 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoST JOSEPH HOSPITAL OF NASHUA NH
NASHUA, NH 03060
NASHUA, NH 03060
33aNPI1093787384assigned 02/02/2006
33bProvider typeAdult Mental Health Clinic/Center
28Total paid$13.00M
24GClaims470,384
24DCodes billed224
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79,269 | $1.55M | |
| 2019 | 89,887 | $2.11M | |
| 2020 | 66,521 | $1.93M | |
| 2021 | 90,709 | $2.48M | |
| 2022 | 86,100 | $2.86M | |
| 2023 | 32,176 | $1.19M | |
| 2024incomplete | 25,722 | $887K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 21,995 | 17,102 | $2.25M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 7,758 | 5,912 | $1.27M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 19,587 | 15,075 | $1.26M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 2,333 | 1,777 | $890K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.1% | 19,151 | 16,924 | $661K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.1% | 12,760 | 10,766 | $531K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.7% | 5,730 | 4,372 | $483K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.1% | 19,803 | 4,912 | $397K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 2,332 | 1,712 | $310K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 8,033 | 6,565 | $310K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 5,792 | 3,397 | $308K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 22,032 | 13,159 | $201K |
212 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 5,683 | $186K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 357 | $185K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 4,604 | $175K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.3% | 10,863 | $174K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 8,799 | $162K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 2,048 | $156K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 6,955 | $155K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 4,981 | $139K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,782 | $126K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 332 | $122K |
| 80053 | Comprehensive metabolic panel | <1% | 22,546 | $120K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,019 | $108K |
| G0378 | Hospital observation service, per hour | <1% | 1,946 | $103K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,188 | $86K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,792 | $78K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,087 | $74K |
| 87631 | <1% | 721 | $71K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,168 | $64K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 954 | $59K |
| 73630 | <1% | 963 | $54K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,504 | $54K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 683 | $47K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,566 | $45K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 168 | $43K |
| 80061 | Lipid panel | <1% | 4,808 | $42K |
| 73610 | <1% | 814 | $42K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 694 | $41K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 10,674 | $41K |
| 73030 | <1% | 783 | $41K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 256 | $39K |
| 97162 | <1% | 1,467 | $39K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,674 | $38K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 898 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,844 | $36K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 138 | $36K |
| 96376 | <1% | 823 | $34K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,771 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,770 | $33K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 507 | $32K |
| 97161 | <1% | 1,213 | $31K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,975 | $30K |
| 72100 | <1% | 508 | $27K | |
| 73560 | <1% | 537 | $27K | |
| 84484 | <1% | 6,418 | $26K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,682 | $26K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,781 | $24K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 56 | $21K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 561 | $21K |
| 80050 | General health panel | <1% | 2,333 | $20K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 322 | $19K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 983 | $19K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,181 | $19K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 970 | $18K |
| 73130 | <1% | 314 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,080 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 794 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,722 | $16K |
| 73110 | <1% | 253 | $16K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 3,033 | $16K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 248 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,815 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,900 | $16K |
| 87428 | <1% | 269 | $16K | |
| 74018 | <1% | 370 | $15K | |
| 76830 | Ultrasound, transvaginal | <1% | 148 | $15K |
| 83690 | <1% | 4,292 | $15K | |
| 87081 | <1% | 3,316 | $15K | |
| 88342 | <1% | 916 | $14K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,005 | $14K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 365 | $13K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 164 | $13K |
| 85027 | <1% | 3,304 | $13K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 683 | $12K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 57 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 524 | $11K |
| 83880 | <1% | 850 | $11K | |
| 86803 | <1% | 1,049 | $10K | |
| 81001 | <1% | 5,789 | $9K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,597 | $9K |
| 93971 | <1% | 70 | $9K | |
| 84439 | <1% | 1,476 | $9K | |
| 81025 | <1% | 2,115 | $8K | |
| 82077 | <1% | 947 | $8K | |
| 82728 | <1% | 856 | $8K | |
| 87186 | <1% | 1,498 | $7K | |
| 83605 | <1% | 1,582 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 198 | $7K |
| 87040 | <1% | 1,519 | $7K | |
| 83735 | <1% | 2,091 | $6K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,315 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,654 | $6K |
| 85610 | <1% | 3,225 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,360 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,338 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,319 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,354 | $5K |
| 84703 | <1% | 1,059 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,248 | $5K |
| 87077 | <1% | 769 | $5K | |
| 73564 | <1% | 41 | $5K | |
| J3490 | Unclassified drugs | <1% | 1,345 | $5K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 305 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 628 | $4K |
| 97035 | <1% | 406 | $4K | |
| 84702 | <1% | 435 | $4K | |
| 82962 | <1% | 3,403 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,523 | $4K |
| 81003 | <1% | 4,291 | $4K | |
| 73502 | <1% | 126 | $4K | |
| 83550 | <1% | 637 | $4K | |
| 83540 | <1% | 823 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,842 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 90 | $3K |
| 92558 | <1% | 234 | $3K | |
| 87088 | <1% | 1,407 | $3K | |
| 85652 | <1% | 1,869 | $3K | |
| 86141 | <1% | 357 | $3K | |
| 86850 | <1% | 520 | $3K | |
| 85379 | <1% | 564 | $3K | |
| 83655 | <1% | 321 | $3K | |
| 86710 | <1% | 292 | $3K | |
| 97116 | <1% | 331 | $3K | |
| 82607 | <1% | 380 | $3K | |
| 80143 | <1% | 340 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 123 | $3K |
| 99177 | <1% | 281 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,057 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 561 | $3K |
| 94760 | <1% | 1,630 | $3K | |
| 80179 | <1% | 300 | $2K | |
| 87070 | <1% | 394 | $2K | |
| 80076 | <1% | 498 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 136 | $2K |
| 86140 | <1% | 632 | $2K | |
| 82043 | <1% | 508 | $2K | |
| 84145 | <1% | 247 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 17 | $2K |
| 93017 | <1% | 20 | $2K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 472 | $2K |
| 90686 | <1% | 1,526 | $2K | |
| 59025 | Fetal non-stress test | <1% | 42 | $2K |
| 86618 | <1% | 142 | $1K | |
| 87340 | <1% | 203 | $1K | |
| 86900 | <1% | 668 | $1K | |
| 11721 | <1% | 222 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 430 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 868 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,085 | $1K |
| 82784 | <1% | 119 | $1K | |
| 81002 | <1% | 973 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 55 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 94 | $1K |
| 83516 | <1% | 99 | $1K | |
| 86901 | <1% | 668 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 39 | $1K |
| 36000 | <1% | 291 | $974.31 | |
| A9270 | Non-covered item or service | <1% | 4,599 | $941.40 |
| 73562 | <1% | 14 | $859.17 | |
| 86039 | <1% | 105 | $836.98 | |
| 87660 | <1% | 57 | $773.27 | |
| 90715 | <1% | 54 | $760.55 | |
| 87510 | <1% | 57 | $736.62 | |
| 87480 | <1% | 57 | $736.60 | |
| 80081 | <1% | 23 | $657.55 | |
| 84153 | <1% | 59 | $617.69 | |
| 76536 | <1% | 17 | $610.22 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $590.41 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 729 | $585.32 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 765 | $565.00 |
| 11056 | <1% | 47 | $504.37 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 390 | $462.57 |
| 94761 | <1% | 350 | $443.99 | |
| 87205 | <1% | 110 | $337.48 | |
| G0008 | Administration of influenza virus vaccine | <1% | 483 | $320.10 |
| 88312 | <1% | 20 | $295.01 | |
| 20610 | <1% | 32 | $283.39 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 47 | $282.80 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 275 | $268.46 |
| 86364 | <1% | 38 | $239.35 | |
| 81015 | <1% | 112 | $225.49 | |
| 97010 | <1% | 31 | $215.13 | |
| 86706 | <1% | 26 | $208.32 | |
| 87147 | <1% | 40 | $199.19 | |
| 82550 | <1% | 41 | $177.31 | |
| 84550 | <1% | 53 | $174.79 | |
| 84481 | <1% | 14 | $174.45 | |
| 90656 | <1% | 246 | $145.98 | |
| 86431 | <1% | 39 | $145.34 | |
| 82140 | <1% | 19 | $128.96 | |
| 82950 | <1% | 40 | $118.24 | |
| 90662 | <1% | 111 | $92.38 | |
| 86592 | <1% | 30 | $83.27 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 148 | $79.82 |
| 92551 | <1% | 18 | $76.83 | |
| 82565 | <1% | 23 | $75.16 | |
| 99306 | Prolong nursin fac eval 15m | <1% | 22 | $73.46 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 28 | $48.95 |
| 82570 | <1% | 12 | $42.86 | |
| 87420 | <1% | 33 | $42.50 | |
| 85018 | <1% | 36 | $39.62 | |
| 87210 | <1% | 19 | $34.16 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 94 | $24.69 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 134 | $0.04 |
| 90677 | <1% | 28 | $0.01 | |
| 1123F | 0% | 662 | $0.00 | |
| 3074F | 0% | 77 | $0.00 | |
| 3078F | 0% | 86 | $0.00 | |
| 90670 | 0% | 25 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 215 | $0.00 |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 203 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 138 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHADLEY, GERARD (VP FINANCE/CFO)
| Provider | Location | Paid |
|---|---|---|
| Brigham and Women's Faulkner Hospital, INC | Boston, MA | $45.90M |
| Brigham and Women's Faulkner Hospital, INC. | Boston, MA | $138K |
| ST Joseph Hospital of Nashua NH | Milford, NH | $62K |
| ST Joseph Hospital of Nashua NH | Nashua, NH | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.